Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) on depression and anxiety in older adults: A systematic review and meta-analysis.

J Behav Ther Exp PsychiatryApr 20, 2026 (epub)
Clinical ResearchGeriatricsPsychiatry

Jieping Ding, Zafar Mehnaz Ali, Ateya Megahed Ibrahim et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) on depressive symptoms in older adults (≥60 years). Three randomized controlled trials (n=178) were included, revealing that MBCT significantly reduced depressive symptom severity compared to control conditions (pooled Hedges g = -0.92, 95% CI -1.30 to -0.55).

Key findings

  • MBCT was associated with significantly lower depressive symptom severity compared to control conditions.
  • Pooled Hedges g for depressive symptoms was -0.92, indicating a strong effect.
  • Evidence for anxiety and quality-of-life outcomes was limited and could not be pooled.

Why it matters

Depression in older adults can be challenging to treat with standard therapies. MBCT offers a promising non-pharmacological approach that may enhance treatment options for this vulnerable population.

Source

PubMed · PMID 42068736

Published in J Behav Ther Exp Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.